| Date: | 10/19/2021 |
|-------|----------------|
| V | Vana . Thining |

Your Name: Zhiping Cai

Manuscript Title: Role of BCAR4 in prostate cancer cell autophagy

| Manuscript number (if known): | |
|-------------------------------|--|
|-------------------------------|--|

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | Time frame: pastNone | 36 months |
| 3 | Royalties or licenses | None | |
| 4 | Consulting fees | None | |

| | T | 1 | |
|----|---|------|--|
| 5 | Payment or honoraria for lectures, presentations, | None | |
| | | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | None | |
| İ | testimony | | |
| Ì | , · | | |
| 7 | Support for attending | None | |
| , | meetings and/or travel | None | |
| | lineetings and/or traver | | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | None | |
| Ì | pending | | |
| | | | |
| 9 | Participation on a Data | None | |
| _ | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | None | |
| 10 | in other board, society, | None | |
| - | committee or advocacy | | |
| | | | |
| | group, paid or unpaid | N. | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | None | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| | | | |

| The authors have no conflicts of interest to declare. | |
|---|--|
| | |
| | |
| | |
| | |

Please place an "X" next to the following statement to indicate your agreement:

Date: 10/19/2021 Your Name: Yapei Wu

Manuscript Title: Role of BCAR4 in prostate cancer cell autophagy

| Manuscript number (if known) | |
|------------------------------|--|
|------------------------------|--|

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None None | pranning or the work |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses | None None | 36 months |
| 3 | Royalties of licerises | None | |
| 4 | Consulting fees | None | |

| | T | 1 | |
|----|---|------|--|
| 5 | Payment or honoraria for lectures, presentations, | None | |
| | | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | None | |
| İ | testimony | | |
| Ì | , · | | |
| 7 | Support for attending | None | |
| , | meetings and/or travel | None | |
| | lineetings and/or traver | | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | None | |
| Ì | pending | | |
| | | | |
| 9 | Participation on a Data | None | |
| _ | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | None | |
| 10 | in other board, society, | None | |
| - | committee or advocacy | | |
| | | | |
| | group, paid or unpaid | N. | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | None | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| | | | |

| The authors have no conflicts of interest to declare. | |
|---|--|
| | |
| | |
| | |
| | |

Please place an "X" next to the following statement to indicate your agreement:

| Date: 10/19/2021 | |
|--------------------|---|
| Your Name: Guangun | J |

Manuscript Title: Role of BCAR4 in prostate cancer cell autophagy

| Manuscript number (if known) | |
|------------------------------|--|
|------------------------------|--|

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | planning of the work |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | Time frame: pastNone | 36 months |
| 3 | Royalties or licenses | None | |
| 4 | Consulting fees | None | |

| | T | 1 | |
|----|------------------------------|------|--|
| 5 | Payment or honoraria for | None | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | None | |
| İ | testimony | | |
| Ì | , · | | |
| 7 | Support for attending | None | |
| , | meetings and/or travel | None | |
| | lineetings and/or traver | | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | None | |
| Ì | pending | | |
| | | | |
| 9 | Participation on a Data | None | |
| _ | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | None | |
| 10 | in other board, society, | None | |
| - | committee or advocacy | | |
| | • | | |
| | group, paid or unpaid | N. | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | None | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| | | | |

| The authors have no conflicts of interest to declare. |
|---|
| |
| |
| |
| |

Please place an "X" next to the following statement to indicate your agreement:

| Date: | 10 | /19 | /2021 |
|-------|----|-----|-------|
| Dute. | | , | , |

Your Name: Gangmin Wang

Manuscript Title: Role of BCAR4 in prostate cancer cell autophagy

| Manuscript number (if known) | |
|------------------------------|--|
|------------------------------|--|

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| 2 | Grants or contracts from any entity (if not indicated | Time frame: pastNone | 36 months |
| 3 | in item #1 above). Royalties or licenses | None | |
| 4 | Consulting fees | None | |

| | T | 1 | |
|----|------------------------------|------|--|
| 5 | Payment or honoraria for | None | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | None | |
| İ | testimony | | |
| Ì | , · | | |
| 7 | Support for attending | None | |
| , | meetings and/or travel | None | |
| | lineetings and/or traver | | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | None | |
| Ì | pending | | |
| | | | |
| 9 | Participation on a Data | None | |
| _ | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | None | |
| 10 | in other board, society, | None | |
| - | committee or advocacy | | |
| | • | | |
| | group, paid or unpaid | N. | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | None | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| | | | |

| The authors have no conflicts of interest to declare. |
|---|
| |
| |
| |
| |

Please place an "X" next to the following statement to indicate your agreement:

Date: 10/19/2021 Your Name: Bing Liu

Manuscript Title: Role of BCAR4 in prostate cancer cell autophagy

| Manuscript number (if known): | |
|-------------------------------|--|
|-------------------------------|--|

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | Time frame: pastNone | 36 months |
| 3 | Royalties or licenses | None | |
| 4 | Consulting fees | None | |

| | T | 1 | |
|----|------------------------------|------|--|
| 5 | Payment or honoraria for | None | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | None | |
| İ | testimony | | |
| Ì | , · | | |
| 7 | Support for attending | None | |
| , | meetings and/or travel | None | |
| | lineetings and/or traver | | |
| | | | |
| | | | |
| | | | |
| 8 | Patents planned, issued or | None | |
| Ì | pending | | |
| | | | |
| 9 | Participation on a Data | None | |
| _ | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | None | |
| 10 | in other board, society, | None | |
| - | committee or advocacy | | |
| | • | | |
| | group, paid or unpaid | N. | |
| 11 | Stock or stock options | None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | None | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| | | | |

| The authors have no conflicts of interest to declare. |
|---|
| |
| |
| |
| |

Please place an "X" next to the following statement to indicate your agreement: